chlorodihydroxypyridine

Known as: 5-Chloro-2,4-dihydroxypyridinediol, CDHP, GIMERACIL 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2014
01219982014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Heterotopic pancreas is most frequently seen in the duodenum, lacking the normal anatomic and vascular structure of the pancreas… (More)
  • figure 1
  • figure 2
Is this relevant?
2009
2009
A new hard problem called the vector decomposition problem (VDP) was recently proposed by Yoshida et al., and it was asserted… (More)
Is this relevant?
2008
2008
While surgical resection is the most effective treatment for gallbladder cancer, most of these cancers are not resectable at the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Review
2008
Review
2008
BACKGROUND Cystic dystrophy in heterotopic pancreas (CDHP) is a rare condition. It has been recently reported as one of the… (More)
Is this relevant?
Review
2007
Review
2007
Cystic dystrophy of heterotopic pancreas is a rare condition that means cystic changes of normal pancreatic tissue, placed in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2002
2002
A potent antioxidant, resveratrol (3,4',5-trihydroxystilbene), was extracted using 80% methanol from peanut roots (Arachis… (More)
Is this relevant?
2002
2002
Squalene was identified by gas chromatography-mass spectrometry and high-performance liquid chromatography (HPLC) spiking… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which… (More)
  • table 1
  • table 3
  • figure 1
  • table 2
Is this relevant?
Highly Cited
1999
Highly Cited
1999
5-Fluorouracil (5-FU) or a 5-FU derivative 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) has been widely prescribed for patients with… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
S-1 is a novel oral anticancer drug, composed of tegafur (FT), gimestat (CDHP) and otastat potassium (Oxo) in a molar ratio of 1… (More)
Is this relevant?